Advertisement
Screener

Lantheus Holdings, Inc. (LNTH) Deferred Revenue Recognized

2.8 / 5 stars · 68/120 Roast Me

Lantheus Holdings, Inc. Deferred Revenue Recognized

Lantheus Holdings, Inc. (LNTH) reported Deferred Revenue Recognized of -$3.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Income Statement › Other Income

us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-06

  • Lantheus Holdings, Inc. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was -$1.33M.
  • Lantheus Holdings, Inc. contract with customer, liability, revenue recognized for the quarter ending 2019-03-31 was $8.00K, a 0.00% change year-over-year.
  • Lantheus Holdings, Inc. contract with customer, liability, revenue recognized for the quarter ending 2018-09-30 was $8.00K.
  • Lantheus Holdings, Inc. contract with customer, liability, revenue recognized for the quarter ending 2018-06-30 was $9.00K.
  • Lantheus Holdings, Inc. contract with customer, liability, revenue recognized for fiscal 2025 was -$3.14M.
  • Lantheus Holdings, Inc. contract with customer, liability, revenue recognized for fiscal 2024 was -$634.00K, a 192.96% decline from fiscal 2023.
  • Lantheus Holdings, Inc. contract with customer, liability, revenue recognized for fiscal 2023 was $682.00K, a 179.51% increase from fiscal 2022.
  • Lantheus Holdings, Inc. contract with customer, liability, revenue recognized for fiscal 2022 was $244.00K, a 639.39% increase from fiscal 2021.
Period endContract with Customer, Liability, Revenue Recognized 3 monthContract with Customer, Liability, Revenue Recognized 6 monthContract with Customer, Liability, Revenue Recognized 9 monthContract with Customer, Liability, Revenue Recognized 12 monthContract with Customer, Liability, Revenue Recognized 12 month as first filed
2026-06-30-$3.23M
10-Q · filed 2026-08-06
2026-03-31-$1.33M
10-Q · filed 2026-05-07
2025-12-31-$3.14M
10-K · filed 2026-02-26
2024-12-31-$634.00K
10-K · filed 2026-02-26
$447.00K
10-K · filed 2025-02-26
2023-12-31$682.00K
10-K · filed 2025-02-26
2022-12-31$244.00K
10-K · filed 2024-02-22
2021-12-31$33.00K
10-K · filed 2023-02-23
2020-12-31$33.00K
10-K · filed 2022-02-24
2019-12-31$33.00K
10-K · filed 2021-02-25
2019-03-31$8.00K
10-Q · filed 2019-04-30
2018-12-31$33.00K
10-K · filed 2020-02-25
2018-09-30$8.00K
10-Q · filed 2018-10-30
$25.00K
10-Q · filed 2018-10-30
2018-06-30$9.00K
10-Q · filed 2018-08-01
$17.00K
10-Q · filed 2018-08-01
2018-03-31$8.00K
10-Q · filed 2019-04-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEOGEN CORP (NEOG)United States$2.979B-247.49
Celldex Therapeutics, Inc. (CLDX)United States$2.471B-9.72
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
BIOMERICA INC (BMRA)United States$0.011B